Protheragen is committed to invest in the early stage first-in-class drug development projects, using our funds based in China. Different from other investment companies, our strategy appreciates the uniqueness of an innovation, helping scientists with bright program ideas and persuasive preclinical results to build their startup business from scratch. We support seed capital to accelerate the project, and can continue bringing in following rounds for late-stage development depending on the project.
● Invest and incubate 100 early stage novel drug R&D projects.
● Each selected project receives US $100-300 million.
Areas of investment:
|Protein/Polypeptide Therapeutics||Immunotherapies||CAR-T Therapies||Stem Cells||Oncolytic Viruses||Gene Therapies||Vaccines||Small Molecules|
Project needs to be innovative and with international IP protection.
No restriction on the disease types.
Consider companies with outsourced early R&D to avoid investment in fixed assets.
Investment fund is for R&D use only.